| [1] |
Luckman SP, Coxon FP, Ebetion FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages[J]. J Bone Miner Res, 1998, 13 (11): 1668-78.
|
| [2] |
Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates[J]. J Pharmacol Exp Ther, 2001, 29 6(2): 235-42.
|
| [3] |
Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells[J]. Cancer Res, 2001, 61 (6): 2602-8.
|
| [4] |
Daubiné F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis[J]. J. Natl Cancer Inst, 2007, 99(4): 322-30.
|
| [5] |
Ottewell PD, Wang N, Brown HK, et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo[J]. Clin Cancer Res, 2014, 20(11): 29 22-32.
|
| [6] |
Kijima T, Koga F, Fujii Y, et al. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1[J]. PLoS One, 2013, 8(5): e64615.
|
| [7] |
Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial[J]. Lancet Oncol, 2011, 12(7): 631-41.
|
| [8] |
Fukai J, Koizumi F, Nakao N. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase[J]. PLoS One, 2014, 9(8): e104538.
|
| [9] |
Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents[J]. Clin Cancer Res, 2012, 18(13): 3524-31.
|
| [10] |
Castella B, Riganti C, Fiore F, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous crosstalk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells[J]. J Immunol, 2011, 187(4): 15 78-90.
|
| [11] |
Kiper HD, Tezcanli Kaymaz B, Gokbulut AA, et al. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells[J]. Biomed Pharmacother, 2013, 67 (6): 527-32.
|
| [12] |
Misso G, Porru M, Stoppacciaro A, et al. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid[J]. Cancer Biol Ther, 2012, 13(14): 1491-500.
|
| [13] |
Beuselinck B, Wolter P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases[J]. Br J Cancer, 2012, 10 7(10): 1665-71.
|
| [14] |
Keizman D, Ish-Shalom M, Pili R, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma[J]. Eur J Cancer, 2012, 48 (7): 1031-7.
|
| [15] |
K o s a k a T, Ya m a k i E , M o g i A , e t al . A c a s e of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combinedadministration of erlotinib and zoledronic acid[J]. Tumori, 2014, 10 0(2): e45-8.
|
| [16] |
Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer[J]. Breast Cancer Res Treat, 2010, 122(1): 18 1-8.
|
| [17] |
Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate[J]. Blood, 2003, 102(6): 22 29-35.
|
| [18] |
Chuah C, Barnes DJ, Kwok M, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells[J]. Leukemia, 2005, 19(11): 1896-904.
|
| [19] |
Melisi D, Caputo R, Damiano V, et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer[J]. Endocr Relat Cancer, 2005, 12(4): 1051-8.
|
| [20] |
Chang JW, Hsieh JJ, Shen YC, et al. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells[J]. Cancer Lett, 2009, 278(1): 17 -26.
|
| [21] |
Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects[J]. Clin Cancer Res, 2010, 16(13): 3420-30.
|
| [22] |
Previdi S, Scolari F, Chilà R, et al. Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model[J]. PLoS One, 2013, 8(11): e79101.
|
| [23] |
Previdi S, Maroni P, Matteucci E, et al. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/ Wnt pathways[J]. Eur J Cancer, 2010, 46(9): 1679-91.
|
| [24] |
Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients[J]. Clin Cancer Res, 2007, 13 (15 Pt 1): 4482-6.
|
| [25] |
Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer[J]. Cancer Res, 2007, 67(15): 74 50-7.
|
| [26] |
Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phaseⅠclinical study[J]. J Immunother, 2011, 34(2): 202-11.
|
| [27] |
Lang JM, Kaikobad MR, Wallace M, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma[J]. Cancer Immunol Immunother, 2011, 60(10): 1447-60.
|
| [28] |
Nakajima J, Murakawa T, Fukami T, et al. A phaseⅠstudy of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells[J]. Eur J Cardiothorac Surg, 2010, 37(5): 1191-7.
|
| [29] |
Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients[J]. Clin Exp Immunol, 2010, 161(2): 290-7.
|
| [30] |
Kobayashi H, Tanaka Y, Yagi J, et al. Phase Ⅰ/Ⅱ study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma[J]. Cancer Immunol Immunother, 2011, 60(8): 10 75-84.
|
| [31] |
Kunzmann V, Smetak M, Kimmel B, et al. Tumor-promoting versus tumor-antagonizing roles of gd T cells in cancer immunotherapy: results from a prospective phase Ⅰ/Ⅱ Trial[J]. J Immunother, 2012, 35(2): 205-13.
|
| [32] |
Li W, Kubo S, Okuda A, et al. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2[J]. J Immunother, 2010, 33(3): 287-96.
|
| [33] |
Di Carlo E, Bocca P, Emionite L, et al. Mechanisms of the antitumor activity of human Vgamma9Vdelta2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma[J]. Mol Ther, 2013, 21(5): 1034-43.
|
| [34] |
Nakazawa T, Nakamura M, Park YS, et al. Cytotoxic human peripheral blood-derived gammadeltaT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma[J]. J Neurooncol, 2014, 116(1): 31-9.
|
下载:
